Comprehensive profiling of the human fecal proteome from IBD patients with DIA-MS enables evaluation of disease-relevant proteins.
Brandon J HarderAnnemarie N LekkerkerkerEllen P CasavantJason A HackneyAllen NguyenJacqueline M McBrideWilliam Rodney MathewsVeronica G AnaniaPublished in: Proteomics. Clinical applications (2024)
Findings from this study not only confirmed the presence of established fecal biomarkers for IBD, such as calprotectin and lactoferrin, but also revealed new fecal proteins from multiple pathways known to be dysregulated in IBD. These novel proteins could serve as potential noninvasive biomarkers to monitor specific aspects of IBD disease activity which could expedite clinical development of novel therapeutic targets.